# Personalis, Inc.: overview PSNL · Nasdaq · CIK 1527753 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/psnl.md) · [Financials](/companies/psnl/financials.md) · [Filings](/companies/psnl/filings.md) · [Insiders](/companies/psnl/insiders.md) Latest reported revenue: [$22.4m](/filings/0001193125-26-332817.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-332817). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [25.7](/filings/0001193125-25-264708.md) | [16.8 d](/filings/0001193125-26-076615.md) | [20.6](/filings/0001193125-26-211896.md) | [17.2](/filings/0001193125-26-332817.md) | [14.5](/filings/0001193125-25-264708.md) | [17.3 d](/filings/0001193125-26-076615.md) | [15.5](/filings/0001193125-26-211896.md) | [22.4](/filings/0001193125-26-332817.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(55.9%)](/filings/0001193125-25-264708.md) | [(107.8%) d](/filings/0001193125-26-076615.md) | [(85.9%)](/filings/0001193125-26-211896.md) | [(126.7%)](/filings/0001193125-26-332817.md) | [(160.7%)](/filings/0001193125-25-264708.md) | [(145.7%) d](/filings/0001193125-26-076615.md) | [(207.9%)](/filings/0001193125-26-211896.md) | [(150.2%)](/filings/0001193125-26-332817.md) | | Net margin | % | [(152.0%)](/filings/0001193125-25-264708.md) | [(97.8%) d](/filings/0001193125-26-076615.md) | [(76.4%)](/filings/0001193125-26-211896.md) | [(116.6%)](/filings/0001193125-26-332817.md) | [(149.4%)](/filings/0001193125-25-264708.md) | [(137.3%) d](/filings/0001193125-26-076615.md) | [(194.1%)](/filings/0001193125-26-211896.md) | [(141.7%)](/filings/0001193125-26-332817.md) | | Diluted EPS | $ per share | [(0.64)](/filings/0001193125-25-264708.md) | not reported | [(0.18)](/filings/0001193125-26-211896.md) | [(0.23)](/filings/0001193125-26-332817.md) | [(0.24)](/filings/0001193125-25-264708.md) | not reported | [(0.29)](/filings/0001193125-26-211896.md) | [(0.30)](/filings/0001193125-26-332817.md) | | Free cash flow | $m | [(6.4) d](/filings/0001193125-25-264708.md) | [(9.0) d](/filings/0001193125-26-076615.md) | [(20.5)](/filings/0001193125-26-211896.md) | [(13.2) d](/filings/0001193125-26-332817.md) | [(23.4) d](/filings/0001193125-25-264708.md) | [(22.3) d](/filings/0001193125-26-076615.md) | [(25.7)](/filings/0001193125-26-211896.md) | [(29.6) d](/filings/0001193125-26-332817.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [85.5](/filings/0000950170-24-022097.md) | [65.0](/filings/0000950170-24-022097.md) | [73.5](/filings/0000950170-25-029221.md) | [84.6](/filings/0001193125-26-076615.md) | [69.6](/filings/0001193125-26-076615.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(76.4%)](/filings/0000950170-24-022097.md) | [(177.6%)](/filings/0000950170-24-022097.md) | [(149.6%)](/filings/0000950170-25-029221.md) | [(80.7%)](/filings/0001193125-26-076615.md) | [(126.4%)](/filings/0001193125-26-076615.md) | | Net margin | % | [(76.3%)](/filings/0000950170-24-022097.md) | [(174.2%)](/filings/0000950170-24-022097.md) | [(147.4%)](/filings/0000950170-25-029221.md) | [(96.1%)](/filings/0001193125-26-076615.md) | [(116.7%)](/filings/0001193125-26-076615.md) | | Diluted EPS | $ per share | [(1.49)](/filings/0000950170-24-022097.md) | [(2.48)](/filings/0000950170-24-022097.md) | [(2.25)](/filings/0000950170-25-029221.md) | [(1.37)](/filings/0001193125-26-076615.md) | [(0.91)](/filings/0001193125-26-076615.md) | | Free cash flow | $m | [(81.9)](/filings/0000950170-24-022097.md) | [(120)](/filings/0000950170-24-022097.md) | [(67.2)](/filings/0000950170-25-029221.md) | [(46.8)](/filings/0001193125-26-076615.md) | [(79.5)](/filings/0001193125-26-076615.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/psnl/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2025-12-22 | [Tempus AI, Inc.](/insiders/1717115.md) | 10% owner | Purchase (P) | 28,000 | $8.93 | $250.0k | [Form 4](/filings/0001193125-26-051798.md) | | 2025-12-19 | [Tempus AI, Inc.](/insiders/1717115.md) | 10% owner | Purchase (P) | 29,641 | $8.39 | $248.7k | [Form 4](/filings/0001193125-26-051798.md) | | 2025-12-18 | [Tempus AI, Inc.](/insiders/1717115.md) | 10% owner | Purchase (P) | 31,430 | $7.91 | $248.6k | [Form 4](/filings/0001193125-26-051798.md) | | 2025-12-17 | [Tempus AI, Inc.](/insiders/1717115.md) | 10% owner | Purchase (P) | 31,650 | $7.86 | $248.8k | [Form 4](/filings/0001193125-26-051798.md) | | 2025-11-25 | [Tempus AI, Inc.](/insiders/1717115.md) | 10% owner | Purchase (P) | 13,888 | $11.00 | $152.8k | [Form 4](/filings/0001193125-26-051798.md) | | 2025-11-25 | [Tempus AI, Inc.](/insiders/1717115.md) | 10% owner | Purchase (P) | 9,712 | $10.08 | $97.9k | [Form 4](/filings/0001193125-26-051798.md) | | 2025-11-24 | [Tempus AI, Inc.](/insiders/1717115.md) | 10% owner | Purchase (P) | 25,225 | $9.87 | $249.0k | [Form 4](/filings/0001193125-26-051798.md) | | 2025-11-21 | [Tempus AI, Inc.](/insiders/1717115.md) | 10% owner | Purchase (P) | 16,599 | $9.74 | $161.7k | [Form 4](/filings/0001193125-26-051798.md) | | 2025-11-21 | [Tempus AI, Inc.](/insiders/1717115.md) | 10% owner | Purchase (P) | 9,900 | $8.84 | $87.5k | [Form 4](/filings/0001193125-26-051798.md) | | 2025-11-20 | [Tempus AI, Inc.](/insiders/1717115.md) | 10% owner | Purchase (P) | 28,827 | $8.63 | $248.8k | [Form 4](/filings/0001193125-26-051798.md) | | 2025-11-19 | [Tempus AI, Inc.](/insiders/1717115.md) | 10% owner | Purchase (P) | 30,645 | $8.12 | $248.8k | [Form 4](/filings/0001193125-26-051798.md) | | 2025-11-18 | [Tempus AI, Inc.](/insiders/1717115.md) | 10% owner | Purchase (P) | 64,750 | $7.67 | $496.6k | [Form 4](/filings/0001193125-26-051798.md) | | 2024-08-16 | [Tempus AI, Inc.](/insiders/1717115.md) | 10% owner | Purchase (P) | 3,500,000 | $5.07 | $17.7m | [Form 4](/filings/0001493152-24-033271.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Merck & Co., Inc.](/funds/310158.md) | 2026-06-30 | $188.2m | 14,044,943 | | Unchanged | | [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $110.8m | 8,271,339 | | Added +327,227 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $94.9m | 7,082,491 | | Added +1,692,606 | | [LIGHTSPEED MANAGEMENT COMPANY, L.L.C.](/funds/1702122.md) | 2026-06-30 | $81.8m | 6,101,850 | | Reduced −2,058,884 | | [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $81.6m | 6,086,315 | | Reduced −1,506,492 | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $53.6m | 4,000,000 | | Added +1,000,000 | | [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $50.2m | 3,747,290 | | Added +258,982 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $40.3m | 3,010,150 | | Added +141,687 | | [Casdin Capital, LLC](/funds/1534261.md) | 2026-06-30 | $34.2m | 2,550,000 | | Added +950,000 | | [KENNEDY CAPITAL MANAGEMENT LLC](/funds/884589.md) | 2026-06-30 | $31.7m | 2,364,282 | | Added +180,710 | ## Recent filings [All 538 filings](/companies/psnl/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-06 | 20:05 ET | [8-K](/filings/0001193125-26-415547.md) | 8.01 Other events | 0001193125-26-415547 | | 2026-08-20 | 20:46 ET | [8-K](/filings/0001193125-26-359300.md) | 8.01 Other events | 0001193125-26-359300 | | 2026-08-04 | 20:11 ET | [10-Q](/filings/0001193125-26-332817.md) | Quarterly report, period 2026-06-30 | 0001193125-26-332817 | | 2026-08-04 | 20:04 ET | [8-K](/filings/0001193125-26-332748.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-332748 | | 2026-07-21 | 16:05 ET | [SCHEDULE 13D/A](/filings/0001193125-26-310289.md) | Ownership report, active investor, amended | 0001193125-26-310289 | | 2026-07-20 | 21:26 ET | [8-K](/filings/0001193125-26-309101.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-309101 | | 2026-07-20 | 13:18 ET | [8-K](/filings/0001193125-26-308488.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-308488 | | 2026-06-10 | 00:24 ET | [SCHEDULE 13D/A](/filings/0001805207-26-000003.md) | Ownership report, active investor, amended | 0001805207-26-000003 | | 2026-05-20 | 20:04 ET | [8-K](/filings/0001193125-26-232533.md) | 8.01 Other events | 0001193125-26-232533 | | 2026-05-13 | 20:52 ET | [8-K](/filings/0001193125-26-221846.md) | 5.07 Shareholder vote results | 0001193125-26-221846 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076615.md), filed Feb 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/788d9ac7-c33c-4a54-8dea-f7ae6d922d01) ## About the filer - CIK: 1527753 - Tickers: PSNL - Exchange: Nasdaq - SIC code: 8071 Services-Medical Laboratories - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.